Mumbai: Zota Healthcare Ltd., a manufacturer of pharmaceutical, nutraceutical, and ayurvedic medicines, held a press briefing on April 5 at the Mumbai Press Club on the topic ‘Vision of Indian healthcare and Zota Healthcare (davaindia) ahead’ and its upcoming milestones in 2023, which are set to redefine the Indian Retail Pharmacy landscape.
Dr Sujit Paul, Group CEO of Zota Healthcare Ltd., briefed a large gathering of media representatives on Zota Healthcare’s (davaindia) vision and the milestones to be achieved in 2023 to redefine the Indian retail pharmacy landscape.
Dr Paul delved deeply into the role of Zota Healthcare Ltd. in the evolution of healthcare in the coming years, the mission of davaindia, the rising costs of healthcare in India, the changing facet of healthcare in various organizations, and the awareness of generic medicines in India, amongst other topics.
Dr Paul stated, “In India, awareness of generic medicine is still very low. As awareness of generic drugs increases, davaindia, the largest private generic pharmacy chain, has a substantial competitive advantage. Also, the comparative cost savings of up to 90 per cent on medicine bills provided by Davaindia will be a significant factor.
According to Dr Paul, Davaindia’s mission is to make affordable, high-quality generic medicines accessible to all citizens of India. People in remote areas should not be denied access to generic medicines, especially as the cost of the Indian healthcare sector and branded medicines rises daily.
“We have been attracting the industry’s top talent to the newly restructured Zota Healthcare Ltd. According to Dr Paul, the appointment of Business Heads for each vertical is the stepping stone to new heights.
Regarding the availability of generic medicines, Dr Paul stated, “Other generic retail players carry branded generic medicines that are still more expensive than those offered by davaindia. Additionally, they must stock multiple molecules for each medicine.
